AMINOSYN 5% 220 MG / 100 ML
L-PHENYLALANINE : 220 MG / 100 ML SERINE : 210 MG / 100 ML L-LYSINE (L-LYSINE ACETATE) : 360 MG / 100 ML L-VALINE : 400 MG / 100 ML TRYPTOPHAN : 80 MG / 100 ML HISTIDINE : 150 MG / 100 ML L-TYROSINE : 44 MG / 100 ML GLYCINE : 640 MG / 100 ML L-PROLINE : 430 MG / 100 ML L-ARGININE : 490 MG / 100 ML L-LEUCINE : 470 MG / 100 ML L-ALANINE : 640 MG / 100 ML METHIONINE : 200 MG / 100 ML L-THREONINE : 260 MG / 100 ML L-ISOLEUCINE : 360 MG / 100 ML · DIN 00404160 · HOSPIRA HEALTHCARE ULC
Health Canada status: CANCELLED POST MARKET
What is AMINOSYN 5%?
AMINOSYN 5% 220 MG / 100 ML contains L-PHENYLALANINE : 220 MG / 100 ML SERINE : 210 MG / 100 ML L-LYSINE (L-LYSINE ACETATE) : 360 MG / 100 ML L-VALINE : 400 MG / 100 ML TRYPTOPHAN : 80 MG / 100 ML HISTIDINE : 150 MG / 100 ML L-TYROSINE : 44 MG / 100 ML GLYCINE : 640 MG / 100 ML L-PROLINE : 430 MG / 100 ML L-ARGININE : 490 MG / 100 ML L-LEUCINE : 470 MG / 100 ML L-ALANINE : 640 MG / 100 ML METHIONINE : 200 MG / 100 ML L-THREONINE : 260 MG / 100 ML L-ISOLEUCINE : 360 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00404160, held by HOSPIRA HEALTHCARE ULC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 29-Jul-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AMINOSYN 5% used for?
Aminosyn 7 5%, 7%, 8.5% and 10% (amino acids for injection 5%, 7%, 8.5% and 10%), Sulfite-Free are indicated for peripheral vein infusion as a source of nitrogen in the intravenous treatment of acute surgical patients. AMINOSYN 7 -RF INJECTION 5.2% (amino acids for injection 5.2% - renal formula), Sulfite-Free is indicated in patients with acute renal failure. Amino acids, when administered with concentrated dextrose solutions are also indicated for central vein infusion as an adjunct in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: (1) the alimentary tract, by the oral, gastrostomy or jejunostomy route, cannot or should not be used, (2) gastrointestinal absorption of protein is impaired, or (3) metabolic requirements for protein are substantially increased, as with extensive burns or in renal failure patients who cannot eat. AMINOSYN 7 7%, 8.5% and 10%, when administered with Dextrose 50% Injection, are designed for central vein infusion only. They are intended to meet the needs of hypermetabolic patients, such as those with burns or trauma.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00404160 |
|---|---|
| Brand name | AMINOSYN 5% |
| Generic / active ingredient | L-PHENYLALANINE : 220 MG / 100 ML SERINE : 210 MG / 100 ML L-LYSINE (L-LYSINE ACETATE) : 360 MG / 100 ML L-VALINE : 400 MG / 100 ML TRYPTOPHAN : 80 MG / 100 ML HISTIDINE : 150 MG / 100 ML L-TYROSINE : 44 MG / 100 ML GLYCINE : 640 MG / 100 ML L-PROLINE : 430 MG / 100 ML L-ARGININE : 490 MG / 100 ML L-LEUCINE : 470 MG / 100 ML L-ALANINE : 640 MG / 100 ML METHIONINE : 200 MG / 100 ML L-THREONINE : 260 MG / 100 ML L-ISOLEUCINE : 360 MG / 100 ML |
| Manufacturer | HOSPIRA HEALTHCARE ULC |
| Strength | 220 MG / 100 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BA01 AMINO ACIDS |
| AHFS class | 40:20.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 29-Jul-2016 |
| Original market date | 1977-12-31 00:00:00 |
How is it stored and handled?
Store between 20°C and 25°C. Do not freeze. Protect from light. Avoid excessive heat.
How is it supplied?
AMINOSYN 7 5% is supplied in 500 and 1000 mL flexible plastic containers; AMINOSYN 7 7% is supplied in 500 mL flexible plastic containers; AMINOSYN 7 8.5% is supplied in 500 mL and 1000 mL flexible plastic containers; AMINOSYN 7 10% is supplied in 500 mL and 1000 mL flexible plastic containers. AMINOSYN 7 -RF INJECTION 5.2% is supplied in 500 mL flexible plastic containers.
What can be used instead?
Other Canadian products sharing ATC code B05BA01 AMINO ACIDS. 4 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 20% PROSOL | 1.18 G / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02141450 |
| ESSEPNA | 1.1 G / 100 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02510324 |
| PRIMENE 10% | 189 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02236875 |
| TRAVASOL | 600 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00872296 |
| 4.25% AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE QUICKMIX | 76 MG / 100 ML | SOLUTION | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | DIN 02013908 |
| 8.5% FREAMINE III | 770 MG / 100 ML | LIQUID | B. BRAUN MEDICAL INC | CANCELLED POST MARKET | DIN 02158647 |
| AMINOSYN | 440 MG / 100 ML | SOLUTION | ICU MEDICAL CANADA INC | CANCELLED POST MARKET | DIN 00454907 |
| AMINOSYN 7% | 690 MG / 100 ML | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00523232 |
| AMINOSYN 8.5% | 624 MG / 100 ML | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00613320 |
| AMINOSYN II | 172 MG / 100 ML | SOLUTION | ICU MEDICAL CANADA INC | DORMANT | DIN 00742619 |
Who else supplies AMINO ACIDS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMINO ACIDS appears in 215 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.